Generic Cosela Availability

Last updated on Jun 11, 2025.

Cosela is a brand name of trilaciclib, approved by the FDA in the following formulation(s):

COSELA (trilaciclib dihydrochloride - powder;intravenous)

• Manufacturer: PHARMACOSMOS
  Approval date: February 12, 2021
  Strength(s): EQ 300MG BASE/VIAL ^[RLD]

Is there a generic version of Cosela available?

No. There is currently no therapeutically equivalent version of Cosela available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cosela. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Transient protection of normal cells during chemotherapy
  Patent 10,085,992
  Issued: October 2, 2018
  Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
  Assignee(s): G1 Therapeutics, Inc.
  

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
• CDK inhibitors
  Patent 10,189,849
  Issued: January 29, 2019
  Inventor(s): Tavares Francis X. & Strum Jay C.
  Assignee(s): G1 Therapeutics, Inc.
  

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug substance
• CDK inhibitors
  Patent 10,189,850
  Issued: January 29, 2019
  Inventor(s): Tavares Francis X. & Strum Jay C.
  Assignee(s): G1 Therapeutics, Inc.
  

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug product
• CDK inhibitors
  Patent 10,927,120
  Issued: February 23, 2021
  Inventor(s): Tavares Francis X. & Strum Jay Copeland
  Assignee(s): GI Therapeutics, Inc.
  

  Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug product
• Transient protection of normal cells during chemotherapy
  Patent 10,966,984
  Issued: April 6, 2021
  Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
  Assignee(s): G1 Therapeutics, Inc.
  

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER
• Transient protection of normal cells during chemotherapy
  Patent 11,040,042
  Issued: June 22, 2021
  Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
  Assignee(s): G1 Therapeutics, Inc.
  

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug product
• Preservation of immune response during chemotherapy regimens
  Patent 11,529,352
  Issued: December 20, 2022
  Inventor(s): Sorrentino; Jessica A. et al.
  Assignee(s): G1 Therapeutics, Inc. (Research Triangle Park, NC)
  

  The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

  Patent expiration dates:

  • July 23, 2039
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
• Transient protection of normal cells during chemotherapy
  Patent 11,717,523
  Issued: August 8, 2023
  Inventor(s): Strum; Jay Copeland et al.
  Assignee(s): G1 Therapeutics, Inc. (Research Triangle Park, NC)
  

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
• Morphic forms of trilaciclib and methods of manufacture thereof
  Patent 12,168,666
  Issued: December 17, 2024
  Inventor(s): Schneider; Stephen et al.
  Assignee(s): G1 Therapeutics, Inc. (Research Triangle Park, NC)
  

  An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

  Patent expiration dates:

  • November 13, 2040
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• CDK inhibitors
  Patent 8,598,186
  Issued: December 3, 2013
  Inventor(s): Tavares Francis X. & Strum Jay C.
  Assignee(s): G1 Therapeutics, Inc.
  

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• CDK inhibitors
  Patent 8,598,197
  Issued: December 3, 2013
  Inventor(s): Tavares Francis X. & Strum Jay C.
  Assignee(s): G1 Therapeutics, Inc.
  

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Transient protection of normal cells during chemotherapy
  Patent 9,487,530
  Issued: November 8, 2016
  Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
  Assignee(s): G1 Therapeutics, Inc.
  

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
  • March 14, 2034
    
    ✓ 
    Patent use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER
• CDK inhibitors
  Patent 9,957,276
  Issued: May 1, 2018
  Inventor(s): Tavares Francis X. & Strum Jay C.
  Assignee(s): GI Therapeutics, Inc.
  

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  Patent expiration dates:

  • October 25, 2031
    
    ✓ 
    Drug substance

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • February 12, 2026 - NEW CHEMICAL ENTITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer